Mitsubishi Tanabe Pharma America Presents Data on Impact of ALS Symptoms on Patients Ability to Independently Conduct Daily Activities
Analysis Shared at 2021 Muscular Dystrophy Association Annual Clinical & Scientific Conference
News provided by
Share this article
Share this article
JERSEY CITY, N.J., March 17, 2021 /PRNewswire/ Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced findings from a new analysis evaluating the impact of symptom progression on the ability of people with amyotrophic lateral sclerosis (ALS) to independently conduct activities of daily living (ADLs). The findings were shared during a virtual presentation at the 2021 Muscular Dystrophy Association Clinical & Scientific Conference. As part of our commitment to patients and their caregivers, MTPA wanted to explore how different disease symptom progression impacts an ALS patients ability to independently perform daily activities, such as cleaning, housework, cooking and traveling outside